Stem Cell


Stem Cell Innovations (SCI) is a network of highly motivated researchers, expert medical professionals, dedicated investors, and innovative engineers working together to create a unique platform that brings together two of the most life-changing innovations of the 21st century: stem cell technology and blockchain technology. Since its initial founding in early 2013 under the name Camden RAD, LLC, SCI has played a crucial role in stem cell research and development around the world, and we has conducted our own domestic and international case studies to further the research in this exciting field. SCI’s activities in the field of stem cell science have directly contributed to advancements in the field, as well as to new stem cell discoveries around the world. Stem cells are a unique type of multicell found in the body of human beings. It is an undifferentiated collection of cells that are capable of providing countless applications in the development of new cells for use in the treatment of diseases and conditions, recovery and restoration of body parts, and with our research and development, many more applications to come. To date, SCI’s areas of study have included orthopedic, neurological, and pulmonary conditions, as well as oncological stem cell applications. Although research conducted by SCI has made strides in these areas of medicine, there remains
an immediate need for further research and development across a vast nexus of medical conditions that impact millions of people around the world. As a leader in stem cell research, SCI plans to continue to organize and participate in many more case studies to aggregate data that can be used to advance this innovative field. Based on our research, we’ve been able to identify countless applications for stem cell therapies including treatments
for conditions such as bone marrow transplants, strokes, traumatic brain injuries, learning disorders, Alzheimer’s disease, missing teeth, wound healing, spinal cord injury, baldness, blindness, deafness, diabetes, Crohn’s disease, and multiple forms of cancer, as well as numerous other conditions. While advancements have been made in stem cell research previously, the introduction of blockchain technology means that more people can gain access to these potentially life-changing treatments -- effectively changing the face of the medical community forever. SCI, along with its affiliates, continues to closely monitors the evolution of stem cell therapy in different medical subspecialties around the world. SCI has created an online community that shares important information from stem cell professionals’ research and contributions across multiple social platforms so there is congruity amongst key players and those that are most interested in stem cell research and the impact it can make on people’s lives. SCI’s network fosters a community where sharing and teaching is encouraged to grow the stem cell industry. SCI’s online community offers access to videos, blogs, and articles about stem cell research that educate, inform, engage, and aim to increase awareness amongst professionals, patients and investors in the proliferation of the stem cell field. Having recognized the potential industry-changing link between stem cell research with the secure nature of blockchain technology, SCI moves to bridge the gap between accessing and understanding of stem cell research and development around the world while creating a collaborative and effective network of key players in the industry.


At SCI, we are devoted to the international research, development, and implementation of stem cell therapy. We are also expanding our network with professionals, labs, clinics, hospitals, and nonprofit organizations. Our ultimate goal at SCI is to connect people who need treatment with the right dedicated solutions and professionals for their unique needs. At SCI, we believe such connections should be convenient and at your fingertips, just as so many other services are in modern society. We imagine a world where each and every person, no matter where they come from, will be able to connect with a Stem Cel Specialist instantly through our Stem Cell Innovations application (SCI Application), and in the same connection be able to decide when and how much confidential information to share with professionals.



Establishment of Camden RAD, LLC, a company devoted to stem cell research and development.

Q4 2017

Camden RAD, LLC is rebranded as Stem Cell Innovations, and a new company is established, based on blockchain technology. Advanced research begins to determine market and development opportunities.

Q1 2018

Attended Token 2049 conference in Hong Kong. Attended Stem Cell Summit at the University of California in Los Angeles (UCLA). Attended CBC conference in San Francisco, CA.

Q2 2018

Attended ICO20 Summit in Santa Monica, CA. Integration of smart contract technology is established. Company headquarters incorporated in Gibraltar, GB. Strategic efforts toward development begins. Interviews with potential medical participants take place.

Q3 2018

Whitelist is scheduled to go live. Token Sale starts.

Q4 2018

Token Sale ends and min max caps are assessed. Distribution of Tokens to participants through ERC20 will commence.

Q1 2019

SCI will begin final testing and reporting based on blockchain technology being used. Creation of a non-identical patient identification factor on Passive Blockchain Node will be initialized. Demo testing for SCI Application v 1.0 will begin.

Q2 2019

Release of the SCI Application v1.1 Enrollment begins for doctors, patients, and stem cell laboratories in the United States

Q3 2019

Release of Market Surveillance strategy for further growth Release SCI Application v2.0 Enrollment begins for professionals, patients, and stem cell laboratories in Middle East and across North Africa. Announcement of first SCI Lab location and franchise expansion plan.

Q4 2019

Announcement of clinical development and research strategy in the stem cell field. Public announcement regarding SCI achievements to date. First ever online synthetic stem cell purchase through the SCI Application. Release SCI Application v3.0, fully functional platform for professionals and patients.

Q1 2020

Stem Cell Lab Evaluation report per first year of operation and development. Release SCI earnings and financials report. Release results of SCI's stem cell research and development to date.

Q2 2020

Expansion of SCI stem cell labs and clinics in China, Japan, South Korea, and India. Begin charging membership fees (payable in Stem Cell Innovations tokens) for professional-facing portion of SCI application.

Q3 2020

Begin second phase of SCI stem cell research and development. Release SCI Application v3.5, including professional-facing component to help practitioners become more involved in the stem cell research space and contribute to the network.

Q4 2020

Expansion and acquisition of SCI stem cell labs and clinics in Europe.

Q1 2021

Release SCI earnings and financials report for second year operation and development. Release public update on SCI stem cell research and development. Stem Cell Lab Evaluation report for second year.

Q2 2021

Release SCI Application v4.0 including: A new platform for medical students, universities, and hospitals to engage with the SCI Application. Fully Functional EMR Worldwide Enforcing HIPPA and expanding of synthetic stem cell delivery to Latin America.